Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 5/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.31 |
| ▸ | ATR | Q13535 | 5/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5418094 | 0.86 | RXRA (0.42) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL30064825 | 0.86 | RXRA (0.41) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL19617703 | 0.86 | RXRA (0.41) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL25428423 | 0.85 | RXRA (0.39) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL23043131 | 0.85 | RXRA (0.39) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL20439334 | 0.84 | RXRA (0.40) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL5407927 | 0.84 | RXRA (0.38) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL5417592 | 0.84 | RXRA (0.40) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL5409247 | 0.84 | RXRA (0.38) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL5413130 | 0.84 | RXRA (0.38) | RXRARXRBRXRGALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3303326-B1 | HETEROCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2020-12-16 | — | — | EP | disclosed |
| EP-3303326-B1 | HETEROCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2020-12-16 | — | — | EP | disclosed |
| CN-107531722-B | Heterocyclic estrogen receptor modulators and uses thereof | 豪夫迈·罗氏有限公司 | 2020-07-17 | — | — | CN | disclosed |
| US-10053451-B2 | Heterocyclic estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2018-08-21 | — | — | US | disclosed |
| EP-3303326-A1 | HETEROCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | H. Hoffnabb-La Roche Ag (CH) | 2018-04-11 | — | — | EP | disclosed |
| US-20160347742-A1 | HETEROCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160347742-A1 | HETEROCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160347742-A1 | HETEROCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-12-01 | — | — | US | disclosed |
| WO-2016189011-A1 | HETEROCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2016-12-01 | — | — | WO | disclosed |
| WO-2016189011-A1 | HETEROCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2016-12-01 | — | — | WO | disclosed |
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | RXRA 1096/4885RXRB 1324/4885RXRG 1147/4885 |
| US-10053451-B2 | Heterocyclic estrogen receptor modulators and uses thereof | ESR2, GPER1, ESRRG | RXRA 47/4885RXRB 48/4885RXRG 39/4885 |
| US-20160347742-A1 | HETEROCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, GPER1, ESRRG | RXRA 47/4885RXRB 48/4885RXRG 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.